Works matching IS 22351795 AND DT 2023 AND VI 12 AND IP 2
Results: 11
APPLE News.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000530731
- Publication type:
- Article
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000530079
- By:
- Publication type:
- Article
Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Elderly Patients with Hepatocellular Carcinoma Benefit from Liver Transplantation as Much as Younger Ones.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000528830
- By:
- Publication type:
- Article
Imaging Diagnosis of Various Hepatocellular Carcinoma Subtypes and Its Hypervascular Mimics: Differential Diagnosis Based on Conventional Interpretation and Artificial Intelligence.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000528538
- By:
- Publication type:
- Article
Surgical Resection or Radiofrequency Ablation for Small Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000527836
- By:
- Publication type:
- Article
Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000527759
- By:
- Publication type:
- Article
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000527403
- By:
- Publication type:
- Article
Atezolizumab and Bevacizumab Combination Therapy and Sequential Conversion Hepatectomy for Advanced Fibrolamellar Hepatocellular Carcinoma Presenting Pseudoprogression.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
PD-1/CTLA-4 Blockade Leads to Expansion of CD8<sup>+</sup>PD-1<sup>int</sup> TILs and Results in Tumor Remission in Experimental Liver Cancer.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000526899
- By:
- Publication type:
- Article
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000526638
- By:
- Publication type:
- Article